I don't think the Type A meeting request and the timing of the Covid-19 ARDS 2nd interim data results is well aligned.
When submitting the request, Mesoblast needs to supply all the info/ data and at the moment, they don't have the Covid-19 ARDS data.
Also, it may be Mesoblast's decision to go for the full approval rather than the conditional approval; and therefore we need to have a friendly dialog with the FDA rather than a threatening or demanding tone in order to obtain the conditional approval via the Accelerated Approval pathway
MSB Trading 2020 - a new dawn, page-8464
-
- There are more pages in this discussion • 4,607 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.569B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12214 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 37660 | 5 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |